ACCESS TO DUODOPA FOR PEOPLE WITH PARKINSON'S DISEASE

That this House believes that people with Parkinson's disease should always have the full range of treatment options open to them; notes with concern that in England people with Parkinson's disease are currently unable to access Duodopa; recognises that Duodopa is a licensed and often life-changing treatment that can give people back their independence when all other treatment options have been exhausted; further recognises that, when people cannot access Duodopa, their health and care needs significantly increase, with significant cost implications; further recognises that the Clinical Priorities Advisory Group review of Duodopa has been characterised by delays and a lack of transparency; and calls on NHS England urgently to review the availability of Duodopa and take action to ensure that people are able to access the treatment.